Stock analysts at Wolfe Research assumed coverage on shares of Moderna (NASDAQ:MRNA - Get Free Report) in a research report issued on Friday, Marketbeat reports. The brokerage set an "underperform" rating and a $40.00 price target on the stock. Wolfe Research's target price indicates a potential upside of 8.55% from the company's current price.
Several other equities research analysts have also recently weighed in on the stock. Hsbc Global Res upgraded shares of Moderna from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $70.00 to $59.00 and set an "underweight" rating on the stock in a research note on Monday, November 4th. Royal Bank of Canada restated a "sector perform" rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. TD Cowen reduced their price target on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a report on Friday, September 13th. Finally, UBS Group reduced their price objective on shares of Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of "Hold" and an average price target of $90.22.
Read Our Latest Analysis on MRNA
Moderna Trading Down 7.3 %
Shares of MRNA stock traded down $2.92 during trading hours on Friday, hitting $36.85. 24,244,768 shares of the company's stock traded hands, compared to its average volume of 4,709,930. The stock's 50 day simple moving average is $59.96 and its 200 day simple moving average is $97.80. The stock has a market cap of $14.18 billion, a PE ratio of -6.42 and a beta of 1.69. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the firm posted ($1.39) earnings per share. The company's revenue for the quarter was up 3.8% on a year-over-year basis. On average, sell-side analysts anticipate that Moderna will post -9.43 EPS for the current year.
Insider Transactions at Moderna
In other news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Moderna
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. Weiss Asset Management LP bought a new position in shares of Moderna during the third quarter worth approximately $2,470,000. Two Sigma Advisers LP bought a new position in shares of Moderna during the third quarter worth approximately $23,825,000. State Street Corp increased its stake in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Royal London Asset Management Ltd. increased its stake in shares of Moderna by 1.3% during the third quarter. Royal London Asset Management Ltd. now owns 339,619 shares of the company's stock worth $22,697,000 after purchasing an additional 4,310 shares during the period. Finally, Motley Fool Asset Management LLC increased its stake in shares of Moderna by 3.9% during the third quarter. Motley Fool Asset Management LLC now owns 15,468 shares of the company's stock worth $989,000 after purchasing an additional 578 shares during the period. Institutional investors own 75.33% of the company's stock.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Stories
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.